31st July 2015
Perjeta now available in EU for use before surgery in early stage aggressive breast cancer. Roche’s new oncology drug Perjeta (pertuzumab) has been approved by the European Commission to treat certain breast cancer patients when used in combination with its ageing drug Herceptin (trastuzumab).
28th July 2015
Sanofi will pay up to $2.2bn to its long-term biotech partner Regeneron to research and market new immunotherapies in cancer. The two firms, which already co-develop and market the newly approved PCKS9 cholesterol drug Praluent (alirocumab), will work together on early-stage testing of a PD-1 drug candidate for undisclosed targets.
JULY 22, 2015
Merck & Co’s anti-PD-1 therapy Keytruda has been approved in Europe for the treatment of advanced skin cancer. Keytruda will compete for market share with BMS’ Opdivo (nivolumab), the first PD-1 inhibitor to bag European approval when it was cleared for advanced melanoma last month.
Jul 15, 2015
Celgene Corp. announced it has signed an agreement to acquire Receptos. Under the terms of the merger, Celgene will pay $232 per share in cash, or a total of approximately $7.2 billion, net of cash acquired
JULY 29, 2015
The FDA has granted Eisai’s promising cancer drug Lenvima breakthrough therapy designation for renal cell carcinoma. The designation is based on the results of a Phase II trial that showed that Lenvima plus Novartis’ Afinitor (everolimus) “significantly” extended progression-free survival (PFS) compared to Afinitor alone
JULY 27, 2015
European regulatory advisors are backing approval of Novartis’ experimental melanoma combination therapy Tafinlar and Mekinist as well as Revolade for severe aplastic anaemia
JULY 17, 2015
Amgen’s leukaemia immunotherapy Blincyto has demonstrated complete remission in a phase II trial testing the drug in patients with Philadelphia chromosome-positive (Ph+) B-cell precursor acute lymphoblastic leukemia (ALL).
July 13, 2015
The US Food and Drug Administration today announced the approval of gefitinib (Iressa, AstraZeneca) for the first-line treatment of patients with metastatic non–small cell lung cancer (NSCLC) whose tumors contain specific types of epidermal growth factor receptor (EGFR) gene mutations.
Jun 30, 2015
Celgene and Juno Therapeutics will enter into a decade-long partnership to develop and commercialize immunotherapies for the treatment of cancer and autoimmune diseases, both companies announced on June 29, 2015. The partnership will focus on the development of CAR T-cell therapies and other programs related to T-cell technology.
8th May 2015
Zykadia (ceritinib) becomes the first treatment option approved in Europe for patients with ALK-positive non-small cell lung cancer (NSCLC) whose disease has progressed despite prior therapy with Pfizer/Merck KGaA’s Xalkori (crizotinib).